We therefore emphasize diagnostic markers with immediate clinical utility (p16/HPV and p53 patterning in SCC; MYB/MYBL1 fusions in AdCC-BG; intestinal immunophenotype in adenocarcinoma) and recommend that extended genomic findings be discussed within a molecular tumor board. This evidence concerns the gene MYBL1 and adrenocortical carcinoma, hereditary.